It need not evolve to be less virulent (selection pressure is transmission, not keeping host alive) so just as dangerous to the immunologically naive *but* those with previous infection/vaccination (thus no longer novel) can experience it as milder. These keep getting conflated.
-
-
I think equity considerations on how we prioritize are super valid and agree kids are low risk (going up with age). I'd disagree that considering childhood vaccination against a novel virus during period of high-circulation is over-medicalization. It's an important consideration.
-
(I guess I'd add that in the US, unlike say UK or Denmark, there is much less public health protection for individuals and families: vaccines are a tool that allow higher individual protection when people can't depend on lower circulation among adults).
End of conversation
New conversation -
-
-
Also it would be nice to see
@Novavax finally apply for EUA and have some data on adolescent boys, could be a better alternative.Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
does it? I remember when Delta was first kicking around we learned a single shot was no longer anywhere near as protective as with Classic.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.